Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation by Seiichi Okabe et al.
JOURNAL OF HEMATOLOGY
& ONCOLOGY
Okabe et al. Journal of Hematology & Oncology  (2015) 8:97 
DOI 10.1186/s13045-015-0190-9LETTER TO THE EDITOR Open AccessAnti-leukemic activity of axitinib against cells
harboring the BCR-ABL T315I point mutation
Seiichi Okabe*, Tetsuzo Tauchi, Yuko Tanaka, Juri Sakuta and Kazuma OhyashikiAbstract
The BCR-ABL; breakpoint cluster region-Abelson point mutation T315I is resistant to ABL tyrosine kinase inhibitors.
However, axitinib, a vascular endothelial growth factor receptor inhibitor, is effective against this mutation. In this study,
we investigated axitinib activity against ponatinib-resistant cells and found that axitinib inhibited cellular growth and
apoptosis in Ba/F3 T315I-mutant cells and T315I-mutant primary samples, but not in ponatinib-resistant Ba/F3 cells and
primary samples. Thus, an alternative strategy may be required to improve the prognosis of Philadelphia-chromosome-
positive leukemia patients harboring BCR-ABL point mutations.
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The BCR-ABL1 fusion gene is a causative oncogene in
chronic myeloid leukemia (CML) and 30–50 % of acute
lymphoblastic leukemia cases [1, 2]. Although ABL tyro-
sine kinase inhibitors (ABL TKIs) such as imatinib, nilo-
tinib, dasatinib, and bosutinib have improved CML
treatment [3], such therapies cannot cure patients with
Philadelphia chromosome (Ph)-positive leukemia because
of leukemia stem cells [4]. Moreover, some patients develop
BCR-ABL point mutations and become resistant to ABL
TKI therapy [5]. In particular, the ABL kinase domain mu-
tation T315I is resistant to imatinib and second-generation
ABL TKIs (e.g., nilotinib, dasatinib, and bosutinib). Accord-
ingly, this mutation is often found in patients with TKI-
resistant disease [6]. A third-generation ABL TKI, ponati-
nib, and omacetaxine which is a semisynthetic form of
homoharringtonine, was recently developed [7]. Ponatinib
is a potent oral tyrosine kinase inhibitor that affects both
unmutated and mutated BCR-ABL [8]; it is effective
against T315I-mutant cells and has been approved for
TKI-resistant or intolerant CML and Ph-positive ALL pa-
tients. Omacetaxine is approved for the treatment of
chronic or accelerated-phase CML refractory to TKIs [7].
Recently, the vascular endothelial growth factor recep-
tor (VEGFR) inhibitor axitinib was found to exhibit anti-
leukemic activity against T315I-mutant disease. In the* Correspondence: okabe@tokyo-med.ac.jp
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creativecommons.org/publicdomain/zero/1.0/comparative effectiveness of axitinib versus sorafenib in
advanced renal cell carcinoma (AXIS) trial [9], axitinib
improved progression-free survival (PFS) compared to
sorafenib, which is an all-multikinase inhibitor that
blocks angiogenesis targets [10], in patients with ad-
vanced renal cell carcinoma (RCC). Axitinib was ap-
proved for the treatment of advanced RCC. Axitinib is
an orally active and potent TKI of VEGFRs 1, 2, and 3
and inhibits BCR-ABL1, especially the T315I variant, via
a distinct binding conformation [11]. In this study, we
investigated whether axitinib could suppress ponatinib-
resistant compound-mutant cells harboring the T315I
mutation. A 72-h axitinib treatment inhibited the growth
of Ba/F3 T315I cells (Fig. 1a). Immunoblot analysis of
axitinib-treated cells revealed dose-dependent decreases
in BCR-ABL, the downstream molecule Crk-L, and ribo-
somal S6 protein phosphorylation and increases in caspase
3 and Poly (ADP-ribose) polymerase (PARP) activity
(Fig. 1b, c, e). Ponatinib and axitinib also induced apop-
tosis, significantly increased caspase activity (Fig. 1d), and
reduced Akt activity (Fig. 1f).
In contrast, clinically available concentrations of axi-
tinib did not inhibit the growth of ponatinib-resistant
Ba/F3 cells (Fig. 1a). Immunoblot analysis revealed that
BCR-ABL, Crk-L, and S6 kinase phosphorylation were
not inhibited by axitinib or ponatinib (Fig. 1b, e). Simi-
larly, no increase in caspase activity or decrease in Akt
activity was observed following axitinib treatment (Fig. 1c,ticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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Fig. 1 Growth inhibition and cellular signaling following axitinib/ponatinib treatment in T315I-mutant and compound-mutant cells. a Ba/F3 T315I
or Ba/F3 ponatinib-resistant (Ba/F3 ponatinib-R) cells were exposed to axitinib or ponatinib for 72 h at the indicated concentrations and subjected
to quantitative cell proliferation analysis. Each result is presented as the mean percentage of proliferation relative to unexposed control cultures.
*P < 0.05 compared to T315I cells. b Ba/F3 T315I or Ba/F3 ponatinib-R cells were treated with ponatinib (10 nM) or axitinib (500 nM) for 24 h. Total
cell extracts were examined via immunoblot analysis with anti-phospho ABL, phospho-Crk-L, phospho-S6, cleaved caspase 3, cleaved PARP, ABL,
Crk-L, and β-actin antibodies. c Caspase activity was analyzed using an ApoAlert® Caspase-3 Colorimetric Assay Kit (Takara Bio Inc. Otsu, Shiga,
Japan) according to the manufacturer’s protocol. Data represent three independent sets of experiments. *P < 0.05 compared to Ba/F3 T315I and
Ba/F3 ponatinib-R cells. d Apoptosis in Ph-positive cell lines was assayed using a FITC Annexin V Apoptosis Detection Kit I™ (BD Pharmingen, San
Jose, CA, USA). The experiments were performed in triplicate. e Ba/F3 T315I or Ba/F3 ponatinib-R cells were treated with axitinib at the indicated
concentrations for 24 h. Total cell extracts were examined via immunoblot analysis with anti-phospho ABL, phospho-Crk-L, phospho-S6, cleaved
caspase 3, cleaved PARP, ABL, Crk-L, and β-actin antibodies. f Akt activity was analyzed using a phospho-AKT 1/2/3 (Ser473) InstantOne™ enzyme-linked
immunosorbent assay kit (Affymetrix, Cleveland, OH, USA) according to the manufacturer’s protocol. Data represent three independent sets of experiments.
*P< 0.05 compared to Ba/F3 T315I and Ba/F3 ponatinib-R cells. g, h T315I-positive or compound-mutant primary cells were subjected to quantitative cell
proliferation analysis after a 72-h exposure to axitinib or ponatinib. Each result is presented as the mean percentage of proliferation relative to unexposed
control cultures. *P< 0.05 compared to control. i T315I-positive or compound-mutant primary cells were treated with axitinib at the indicated
concentrations for 24 h. Total cell extracts were examined via immunoblot analysis with anti-phospho-Crk-L, phospho-S6, cleaved PARP, and
β-actin antibodies
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these cells (Fig. 1d).
We next evaluated primary T315I-mutant and ponatinib-
resistant compound-mutant samples. Axitinib potently
inhibited the growth of T315I-mutant primary cells in a
dose-dependent manner (Fig. 1g). Immunoblot analysis fur-
ther revealed reduced Crk-L and S6 kinase phosphorylation
after axitinib or ponatinib treatment (Fig. 1i). In contrast,
the growth of ponatinib-resistant primary cells was not af-
fected by ponatinib or axitinib (Fig. 1h). Immunoblotting
revealed that neither ponatinib nor axitinib affected the
phosphorylation of Crk-L and S6 kinase in ponatinib-
resistant cells (Fig. 1i).
In CML, ABL TKI resistance is frequently caused by
ABL kinase domain mutations. The T315I mutation is
resistant to all ABL TKIs except ponatinib. However, we
previously described ponatinib-resistant cells resulting
from a BCR-ABL compound mutation [12]. Although
axitinib, which is currently being investigated for efficacy
in patients with Ph-positive T315I-mutant leukemia, in-
duced apoptosis in T315I-mutant cells, it was ineffective
against cells with a compound mutation including T315I.
An alternative strategy will be required to improve the
prognosis of patients with Ph-positive, BCR-ABL-mutant
leukemia. Current evidence to direct the management
of ABL TKI-resistant disease, particularly those harbor-
ing T315I and compound mutations, is limited. New
molecular-targeted drugs and an understanding of ABL
TKI resistance mechanisms are required to apply an ap-
propriate therapeutic approach.
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